Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With Definitely EGFR T790M State Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an EGFR TKI Agent
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Avitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 29 Sep 2017 Planned number of patients changed from 172 to 294.
- 29 Sep 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2019.
- 29 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.